Studies with herpes zoster vaccines in immune compromised patients

References

• Levin MJ. Zoster Vaccine. In: Plotkin S, Orenstein W, Offitt P, et al., editors. Vaccines. 7th ed. Philadelphia: Elsevier; 2017. p. 1268–1281.
   Google Scholar
• Gershon AA, Gershon MD. Pathogenesis and current approaches to control of varicella-zoster virus infections. Clin Microbiol Rev. 2013;26(4):728–743.
   PubMed Web of Science ®Google Scholar
• Weinberg A, Levin MJ. VZV T cell-mediated immunity. Curr Top Microbiol Immunol. 2010;342:341–357.
   PubMed Web of Science ®Google Scholar
• Weinberg A, Lazar AA, Zerbe GO, et al. Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses. J Infect Dis. 2010;201(7):1024–1030.
   PubMed Web of Science ®Google Scholar
• Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341–1349.
   PubMed Web of Science ®Google Scholar
• Chen SY, Suaya JA, Li Q, et al. Incidence of herpes zoster in patients with altered immune function. Infection. 2014;42(2):325–334.
   PubMed Web of Science ®Google Scholar
• Forbes HJ, Thomas SL, Smeeth L, et al. A systematic review and meta-analysis of risk factors for postherpetic neuralgia. Pain. 2016;157:30–54.
   PubMed Web of Science ®Google Scholar
• Schmader KE, Levin MJ, Gnann JW Jr., et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012;54(7):922–928.
   Web of Science ®Google Scholar
• Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–2284.
   PubMed Web of Science ®Google Scholar
• Baxter F, Bartlett J, Fireman B, et al. Effectiveness of live zoster vaccine in preventing herpes zoster. Poster Abstract 1928. In: IDWeek 2015. (San Diego, 2015)
   Google Scholar
• Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis. 2008;197(6):825–835.
   PubMed Web of Science ®Google Scholar
• Tseng HF, Smith N, Harpaz R, et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. Jama. 2011;305(2):160–166.
   PubMed Web of Science ®Google Scholar
• Langan SM, Smeeth L, Margolis DJ, et al. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med. 2013;10(4):e1001420.
   PubMed Web of Science ®Google Scholar
• Marin M, Yawn BP, Hales CM, et al. Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status. Hum Vaccin Immunother. 2015;11(5):1157–1164.
   PubMed Web of Science ®Google Scholar
• Tseng HF, Harpaz R, Luo Y, et al. Declining effectiveness of herpes zoster vaccine in adults aged >/=60 years. J Infect Dis. 2016;213:1872–1875.
   PubMed Web of Science ®Google Scholar
• Marin M, Guris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. (2007);56(RR-4): 1–40.
   Google Scholar
• Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2008;57(RR–5):1–30; quiz CE32-34.
   PubMedGoogle Scholar
• Jura E, Chadwick EG, Josephs SH, et al. Varicella-zoster virus infections in children infected with human immunodeficiency virus. Pediatr Infect Dis J. 1989;8(9):586–590.
   PubMed Web of Science ®Google Scholar
• Feldman S, Hughes WT, Daniel CB. Varicella in children with cancer: seventy-seven cases. Pediatrics. 1975;56(3):388–397.
   PubMed Web of Science ®Google Scholar
• Maves RC, Tripp MS, Dell TG, et al. Disseminated vaccine-strain varicella as initial presentation of the acquired immunodeficiency syndrome: a case report and review of the literature. J Clin Virol. 2014;59(1):63–66.
   PubMed Web of Science ®Google Scholar
• Merck & Co I. Zostavax (Zoster vaccine live) product insert. In: www.merck.com. ( online, 2014) 1–12.
   Google Scholar
• Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):e44–e100.
   PubMed Web of Science ®Google Scholar
• Patel NC, Hertel PM, Estes MK, et al. Vaccine-acquired rotavirus in infants with severe combined immunodeficiency. N Engl J Med. 2010;362(4):314–319.
   PubMed Web of Science ®Google Scholar
• Shiraki K, Matsui S, Aiba N. Susceptibility of Oka varicella vaccine strain to antiviral drugs. Vaccine. 1993;11(14):1380–1382.
   PubMed Web of Science ®Google Scholar
• Curtis KK, Connolly MK, Northfelt DW. Live, attenuated varicella zoster vaccination of an immunocompromised patient. J Gen Intern Med. 2008;23(5):648–649.
   PubMed Web of Science ®Google Scholar
• Costa E, Buxton J, Brown J, et al. Fatal disseminated varicella zoster infection following zoster vaccination in an immunocompromised patient. BMJ Case Reports, (2016).
   Google Scholar
• Young EJ. Risk of disseminated disease in immunosuppressed patients receiving live zoster vaccine. Mayo Clin Proc. 2016;91(7):971.
   PubMed Web of Science ®Google Scholar
• Levin MJ, Gershon AA, Weinberg A, et al. Immunization of HIV-infected children with varicella vaccine. J Pediatr. 2001;139(2):305–310.
   PubMed Web of Science ®Google Scholar
• Levin MJ, Gershon AA, Weinberg A, et al. Administration of live varicella vaccine to HIV-infected children with current or past significant depression of CD4(+) T cells. J Infect Dis. 2006;194(2):247–255.
   PubMed Web of Science ®Google Scholar
• Bekker V, Westerlaken GH, Scherpbier H, et al. Varicella vaccination in HIV-1-infected children after immune reconstitution. Aids. 2006;20(18):2321–2329.
   PubMed Web of Science ®Google Scholar
• Armenian SH, Han JY, Dunaway TM, et al. Safety and immunogenicity of live varicella virus vaccine in children with human immunodeficiency virus type 1. Pediatr Infect Dis J. 2006;25(4):368–370.
   PubMed Web of Science ®Google Scholar
• Taweesith W, Puthanakit T, Kowitdamrong E, et al. The immunogenicity and safety of live attenuated varicella-zoster virus vaccine in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2011;30(4):320–324.
   PubMed Web of Science ®Google Scholar
• Knorr A, Hutchison E, Finn A. Varicella vaccination for HIV-infected children. Arch Dis Child. 2008;93(9):812.
   PubMed Web of Science ®Google Scholar
• Son M, Shapiro ED, LaRussa P, et al. Effectiveness of varicella vaccine in children infected with HIV. J Infect Dis. 2010;201(12):1806–1810.
   PubMed Web of Science ®Google Scholar
• Gershon AA, Levin MJ, Weinberg A, et al. A phase I-Ii study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous varicella. Pediatr Infect Dis J. 2009;28(7):653–655.
   PubMed Web of Science ®Google Scholar
• Weinberg A, Levin MJ, Macgregor RR. Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV-infected adults. Hum Vaccin. 2010;6(4):318–321.
   PubMed Web of Science ®Google Scholar
• Benson CA, Hua L, Andersen J, et al. Zostavax is generally safe and immunogenic in HIV+ adults virologically suppressed on ART: results of a Phase 2, randomized, double-blind, placebo-controlled trial. (Conference on Retroviruses and Opportunistic Infections (CROI), 19th CROI, 2012 Mar 5–8, Seattle, WA., 2012)
   Google Scholar
• Van Assen S, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70(3):414–422.
   PubMed Web of Science ®Google Scholar
• McNutt R. Shingles vaccine for autoimmune disease patients. Update on herpes zoster (shingles) vaccine for autoimmune disease patients. ( Online, 2012) 2.
   Google Scholar
• Singh JA, Saag KG, Bridges SL Jr., et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis & Rheumatology. 2016;68(1):1–26.
   PubMed Web of Science ®Google Scholar
• NCCN. NCCN guidelines for supportive care: survivorship. (National Comprehensive Cancer Network, Inc., Online, 2013)
   Google Scholar
• Gov.UK/Publications. Shingles: the Green Book Chapter 28a. In: Green Book (Public Health England, 2015) 1–16.
   Google Scholar
• (ATAGI) ATAGoI. 1.24 Zoster (herpes zoster). In: Australian Immunisation Handbook, 10th Edition. (Australian Government Department of Health, online, 2015)
   Google Scholar
• NACI. An advisory committee statement (ACS) - National Advisory Committee on Immunization (NACI): update on the use of herpes zoster vaccine (Government of Canada, online, 2014)
   Google Scholar
• Canada PHAo. Update on the use of herpes zoster vaccine. An Advisory Committee Statement (ACS) - National Advisory Committee on Immunization (NACI). (National Advisory Committee on Immunizations (NACI), Canadian Government, 2014)
   Google Scholar
• Oxman MN, Schmader KE. Editorial commentary: zoster vaccine in immunocompromised patients: time to reconsider current recommendations. Clin Infect Dis. 2014;59(7):920–922.
   PubMed Web of Science ®Google Scholar
• Lobermann M, Borso D, Hilgendorf I, et al. Immunization in the adult immunocompromised host. Autoimmun Rev. 2012;11(3):212–218.
   PubMed Web of Science ®Google Scholar
• Bijl M, Agmon-Levin N, Dayer JM, et al. Vaccination of patients with auto-immune inflammatory rheumatic diseases requires careful benefit-risk assessment. Autoimmun Rev. 2012;11(8):572–576.
   PubMed Web of Science ®Google Scholar
• Cohen JI. Strategies for herpes zoster vaccination of immunocompromised patients. J Infect Dis. 2008;197(Suppl 2):S237–S241.
   PubMed Web of Science ®Google Scholar
• Duchet-Niedziolka P, Launay O, Coutsinos Z, et al. Vaccination in adults with auto-immune disease and/or drug related immune deficiency: results of the GEVACCIM Delphi survey. Vaccine. 2009;27(10):1523–1529.
   PubMed Web of Science ®Google Scholar
• Koenig HC, Garland JM, Weissman D, et al. Vaccinating HIV patients: focus on human papillomavirus and herpes zoster vaccines. AIDS Reviews. 2013;15(2):77–86.
   PubMed Web of Science ®Google Scholar
• Levin MJ, Anderson JP, Seage GR 3rd, et al. Short-term and long-term effects of highly active antiretroviral therapy on the incidence of herpes zoster in HIV-infected children. J Acquir Immune Defic Syndr. 2009;50(2):182–191.
   PubMed Web of Science ®Google Scholar
• Blank LJ, Polydefkis MJ, Moore RD, et al. Herpes zoster among persons living with HIV in the current antiretroviral therapy era. J Acquir Immune Defic Syndr. 2012;61(2):203–207.
   PubMed Web of Science ®Google Scholar
• Grabar S, Tattevin P, Selinger-Leneman H, et al. Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort. Clin Infect Dis. 2015;60(8):1269–1277.
   PubMed Web of Science ®Google Scholar
• Weinberg A, Huang S, Song LY, et al. Immune correlates of herpes zoster in HIV-infected children and youth. J Virol. 2012;86(5):2878–2881.
   PubMed Web of Science ®Google Scholar
• Editors. Corrections to article Rubin, et al. CID 2014:58-e44-100. Clin Infect Dis. 2014;59(1):144–145.
   Web of Science ®Google Scholar
• Munshi N, Longo DL, Anderson KD. Plasma cell disorders. In: Longo D, Jameson J, Loscalzo J, et al., editors. Harrison’s principles of internal medicine. 19th ed. New York: McGraw-Hill; 2015. p. 710–719.
   Google Scholar
• Longo D. Malignancies of lymphoid cells. In: Long D, Jameson J, Loscalzo J, et al., editors. Harrison’s principles of internal medicine. 19th ed. New York: McGraw-Hill; 2015. p. 695–710.
   Google Scholar
• Wadhwa PD, Morrison VA. Infectious complications of chronic lymphocytic leukemia. Semin Oncol. 2006;33(2):240–249.
   PubMed Web of Science ®Google Scholar
• Habel LA, Ray GT, Silverberg MJ, et al. The epidemiology of herpes zoster in patients with newly diagnosed cancer. Cancer Epidemiology, Biomarkers & Prevention: a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology. 2013;22(1):82–90.
   PubMed Web of Science ®Google Scholar
• Yenikomshian MA, Guignard AP, Haguinet F, et al. The epidemiology of herpes zoster and its complications in Medicare cancer patients. BMC Infect Dis. 2015;15:106.
   PubMed Web of Science ®Google Scholar
• Naidus E, Damon L, Schwartz BS, et al. Experience with use of Zostavax((R)) in patients with hematologic malignancy and hematopoietic cell transplant recipients. Am J Hematol. 2012;87(1):123–125.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Wang FZ, Nilsson C, et al. Vaccination of autologous stem cell transplant recipients with live varicella vaccine: a pilot study. Support Care in Cancer. 2003;11(11):739–741.
   PubMed Web of Science ®Google Scholar
• Sasadeusz J, Prince HM, Schwarer A, et al. Immunogenicity and safety of a two-dose live attenuated varicella vaccine given to adults following autologous hematopoietic stem cell transplantation. Transpl Infect Dis. 2014;16(6):1024–1031.
   PubMed Web of Science ®Google Scholar
• Sauerbrei A, Prager J, Hengst U, et al. Varicella vaccination in children after bone marrow transplantation. Bone Marrow Transplant. 1997;20(5):381–383.
   PubMed Web of Science ®Google Scholar
• Kussmaul SC, Horn BN, Dvorak CC, et al. Safety of the live, attenuated varicella vaccine in pediatric recipients of hematopoietic SCTs. Bone Marrow Transplant. 2010;45(11):1602–1606.
   PubMed Web of Science ®Google Scholar
• Chou JF, Kernan NA, Prockop S, et al. Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT). Biol Blood Marrow Transplant. 2011;17(11):1708–1713.
   PubMed Web of Science ®Google Scholar
• Issa NC, Marty FM, Leblebjian H, et al. Live attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2014;20(2):285–287.
   PubMed Web of Science ®Google Scholar
• Koc Y, Miller KB, Schenkein DP, et al. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant. 2000;6(1):44–49.
   PubMed Web of Science ®Google Scholar
• Blennow O, Fjaertoft G, Winiarski J, et al. Varicella-zoster reactivation after allogeneic stem cell transplantation without routine prophylaxis–the incidence remains high. Biol Blood Marrow Transplant. 2014;20(10):1646–1649.
   PubMedGoogle Scholar
• Vermont CL, Jol-van der Zijde EC, Hissink Muller P, et al. Varicella zoster reactivation after hematopoietic stem cell transplant in children is strongly correlated with leukemia treatment and suppression of host T-lymphocyte immunity. Transpl Infectious Disease: Official Journal Transplant Soc. 2014;16(2):188–194.
   PubMed Web of Science ®Google Scholar
• Truong Q, Veltri L, Kanate AS, et al. Impact of the duration of antiviral prophylaxis on rates of varicella-zoster virus reactivation disease in autologous hematopoietic cell transplantation recipients. Ann Hematol. 2014;93(4):677–682.
   PubMed Web of Science ®Google Scholar
• Kawamura K, Hayakawa J, Akahoshi Y, et al. Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus and varicella zoster virus diseases after autologous hematopoietic stem cell transplantation. Int J Hematol. 2015;102(2):230–237.
   PubMed Web of Science ®Google Scholar
• Boeckh M, Kim HW, Flowers ME, et al. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation–a randomized double-blind placebo-controlled study. Blood. 2006;107(5):1800–1805.
   PubMed Web of Science ®Google Scholar
• Van Besouw NM, Verjans GM, Zuijderwijk JM, et al. Systemic varicella zoster virus reactive effector memory T-cells impaired in the elderly and in kidney transplant recipients. J Med Virol. 2012;84(12):2018–2025.
   PubMed Web of Science ®Google Scholar
• Kuo CC, Lee CT, Lee IM, et al. Risk of herpes zoster in patients treated with long-term hemodialysis: a matched cohort study. Am J Kidney Dis. 2012;59(3):428–433.
   PubMed Web of Science ®Google Scholar
• Lin SY, Liu JH, Lin CL, et al. A comparison of herpes zoster incidence across the spectrum of chronic kidney disease, dialysis and transplantation. Am J Nephrol. 2012;36(1):27–33.
   PubMed Web of Science ®Google Scholar
• Forbes HJ, Bhaskaran K, Thomas SL, et al. Quantification of risk factors for herpes zoster: population based case-control study. Bmj. 2014;348:g2911.
   PubMed Web of Science ®Google Scholar
• CDC. Guidelines for vaccinating kidney dialysis patients and patients with chronic kidney disease. In: CDC. Centers for Disease Control and Prevention. ( online, 2012)
   Google Scholar
• Tseng HF, Luo Y, Shi J, et al. Effectiveness of herpes zoster vaccine in patients 60 years and older with end-stage renal disease. Clin Infect Dis. 2016;62(4):462–467.
   PubMed Web of Science ®Google Scholar
• Yun H, Yang S, Chen L, et al. Risk of herpes zoster in autoimmune and inflammatory diseases: implications for vaccination. Arthritis & Rheumatology (Hoboken, N.J.). 2016;68(9):2328–2337.
   PubMed Web of Science ®Google Scholar
• Yun H, Xie F, Delzell E, et al. Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res. 2015;67(5):731–736.
   PubMed Web of Science ®Google Scholar
• Shalom G, Zisman D, Bitterman H, et al. Systemic therapy for psoriasis and the risk of herpes zoster: a 500,000 person-year study. JAMA Dermatology. 2015;151(5):533–538.
   PubMed Web of Science ®Google Scholar
• Che H, Lukas C, Morel J, et al. Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis. Joint Bone Spine. 2014;81(3):215–221.
   PubMed Web of Science ®Google Scholar
• Pappas DA, Hooper MM, Kremer JM, et al. Herpes Zoster reactivation in patients with rheumatoid arthritis: analysis of disease characteristics and disease-modifying antirheumatic drugs. Arthritis Care Res. 2015;67(12):1671–1678.
   Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica. 2015;100(4):479–488.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis & Rheumatology. 2014;66(10):2675–2684.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Xie F, Yun H, et al. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1843–1847.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Baddley JW, Chen L, et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. Jama. 2013;309(9):887–895.
   PubMed Web of Science ®Google Scholar
• Arvin AM, Wolinsky JS, Kappos L, et al. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol. 2015;72(1):31–39.
   PubMed Web of Science ®Google Scholar
• Yun H, Xie F, Baddley JW, et al. Longterm effectiveness of herpes zoster vaccine among patients with autoimmune and inflammatory diseases. J Rheumatol. 2017;44(7):1083–1087.
   PubMed Web of Science ®Google Scholar
• Wine-Lee L, Keller SC, Wilck MB, et al. From the medical board of the national psoriasis foundation: vaccination in adult patients on systemic therapy for psoriasis. J Am Acad Dermatol. 2013;69(6):1003–1013.
   PubMed Web of Science ®Google Scholar
• Guthridge JM, Cogman A, Merrill JT, et al. Herpes zoster vaccination in SLE: a pilot study of immunogenicity. J Rheumatol. 2013;40(11):1875–1880.
   PubMed Web of Science ®Google Scholar
• Sotelo J. On the viral hypothesis of multiple sclerosis: participation of varicella-zoster virus. J Neurol Sci. 2007;262(1–2):113–116.
   PubMed Web of Science ®Google Scholar
• Sotelo J, Ordonez G, Pineda B. Varicella-zoster virus at relapses of multiple sclerosis. J Neurol. 2007;254(4):493–500.
   PubMed Web of Science ®Google Scholar
• Rutschmann OT, McCrory DC, Matchar DB. Immunization and MS: a summary of published evidence and recommendations. Neurology. 2002;59(12):1837–1843.
   PubMed Web of Science ®Google Scholar
• Farez MF, Correale J. Immunizations and risk of multiple sclerosis: systematic review and meta-analysis. J Neurol. 2011;258(7):1197–1206.
   PubMed Web of Science ®Google Scholar
• Ross R, Dawood M, Cheang M, et al. Antibody response in seropositive multiple sclerosis patients vaccinated with attenuated live varicella zoster virus. Can J Infect Dis. 1996;7(5):303–306.
   PubMedGoogle Scholar
• McGraw C, Inglese M, Hannigan C, et al. An open-label observational pilot study to evaluate the safety and immunogenicity of the herpes zoster vaccine in patients with multiple sclerosis. In: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. (ECTRIMS, Lyon, France, 2012)
   Google Scholar
• Tseng HF, Tartof S, Harpaz R, et al. Vaccination against zoster remains effective in older adults who later undergo chemotherapy. Clin Infect Dis. 2014;59(7):913–919.
   PubMed Web of Science ®Google Scholar
• Lindsey S, Oufnac B, Walker H Safety of Zoster vaccination administration in rheumatic patients on current biologic therapy. In: American College of Rheumatology. (American College of Rheumatology, Boston, 2014)
   Google Scholar
• Redman RL, Nader S, Zerboni L, et al. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis. 1997;176(3):578–585.
   PubMed Web of Science ®Google Scholar
• Hata A, Asanuma H, Rinki M, et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med. 2002;347(1):26–34.
   PubMed Web of Science ®Google Scholar
• Mullane KM, Winston DJ, Wertheim MS, et al. Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults. J Infect Dis. 2013;208(9):1375–1385.
   PubMed Web of Science ®Google Scholar
• Haumont M, Jacquet A, Massaer M, et al. Purification, characterization and immunogenicity of recombinant varicella-zoster virus glycoprotein gE secreted by Chinese hamster ovary cells. Virus Res. 1996;40(2):199–204.
   PubMed Web of Science ®Google Scholar
• Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity. 2010;33(4):492–503.
   PubMed Web of Science ®Google Scholar
• Didierlaurent AM, Collignon C, Bourguignon P, et al. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. J Immunol. 2014;193(4):1920–1930.
   PubMed Web of Science ®Google Scholar
• Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372(22):2087–2096.
   PubMed Web of Science ®Google Scholar
• Cunningham AL, Lal H, Kovac M, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375(11):1019–1032.
   PubMed Web of Science ®Google Scholar
• Berkowitz EM, Moyle G, Stellbrink HJ, et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis. 2015;211(8):1279–1287.
   PubMed Web of Science ®Google Scholar
• Stadtmauer EA, Sullivan KM, Marty FM, et al. A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood. 2014;124(19):2921–2929.
   PubMed Web of Science ®Google Scholar